LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study Rachid Berair (Birmingham, United Kingdom), Rachid Berair, Sherif Gonem, Amisha Singapuri, Ruth Hartley, Marie Laurencin, Gerald Bacher, Bjoern Holzhauer, Michelle Bourne, Vijay Mistry, Ian Pavord, Adel Mansur, Andrew Wardlaw, Salman Siddiqui, Richard Kay, Chris Brightling
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rachid Berair (Birmingham, United Kingdom), Rachid Berair, Sherif Gonem, Amisha Singapuri, Ruth Hartley, Marie Laurencin, Gerald Bacher, Bjoern Holzhauer, Michelle Bourne, Vijay Mistry, Ian Pavord, Adel Mansur, Andrew Wardlaw, Salman Siddiqui, Richard Kay, Chris Brightling. LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study. Eur Respir J 2015; 46: Suppl. 59, 290
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
LATE-BREAKING ABSTRACT: Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTh2) antagonist QAW039 in eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children Source: International Congress 2016 – Mechanisms of disease Year: 2016
A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Inhaled fluticasone propionate (FP) restores angiogenesis in the airway lamina propria of current smokers with COPD: A randomized controlled trial Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Efficacy and safety of abediterol, a long-acting beta2 -adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Study on sputum differential counts in asthmatics controlled & uncontrolled on inhaled corticosteroids Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: A pilot tudy Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013
Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Expression of mRNA chemokine and their receptors in nasopharingeal brush-biopsies represents age of bronchial asthma patients Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016
Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016